Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4604475 | 0.83 | CCR3 (0.58) | SLC6A3KMT2APRMT3 | |
| SCHEMBL4900580 | 0.78 | CNR1 (0.60) | SLC6A3KMT2AFPR2CNR1RAB9A | |
| SCHEMBL4605025 | 0.72 | KMT2A (0.50) | SLC6A3KMT2AFPR2CNR1RAB9A | |
| SCHEMBL4607225 | 0.71 | CCR3 (0.62) | SLC6A3KMT2ACNR1 | |
| SCHEMBL11639507 | 0.70 | RXFP1 (0.51) | KMT2ARAB9ANPC1MAPTCYP1A2 | |
| SCHEMBL4881257 | 0.67 | HDAC3 (0.49) | KMT2ARAB9ANPC1MAPTCYP2D6 | |
| SCHEMBL4891370 | 0.67 | KMT2A (0.45) | KMT2AFPR2CNR1RAB9ANPC1 | |
| SCHEMBL7566619 | 0.67 | MAPT (0.81) | KMT2AFPR2CNR1RAB9ANPC1 | |
| SCHEMBL27740395 | 0.66 | TDP1 (0.48) | KMT2ARAB9ANPC1MAPTCYP1A2 | |
| SCHEMBL16946646 | 0.66 | CNR1 (0.74) | KMT2AFPR2CNR1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | WEIGAND KLAUS | 2008-12-11 | — | — | US | disclosed |
| EP-1943235-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Novartis AG (CH) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007048771-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | CCR3, CCR1, CCR4 | SLC6A3 4291/4885KMT2A 4826/4885FPR2 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.